This is a routine post-annual meeting filing with no material trading implications. The ESPP share increase is standard and immaterial relative to market cap. Monitor for any future insider selling patterns following the board resignation, though the departure was explicitly non-disagreement.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $70.54entry
- T+1 · 6mo ago −1.96%α −2.10% · $69.16
- T+5 · 5mo ago +4.41%α +7.16% · $73.65
- T+20 · 5mo ago +25.86%α +27.16% · $88.78
- T+60 · 3mo ago +52.20%α +50.97% · $107.36
Price Chart
How similar events traded
Executive Summary
Spyre Therapeutics held its 2026 Annual Meeting on May 27, 2026, where stockholders approved the amended and restated 2016 Employee Stock Purchase Plan (AR ESPP), adding 1,056,096 shares to the reserve. Director Peter Harwin resigned effective the same date, with no disagreement cited, and the board was reduced from eight to seven members. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the Amended and Restated 2016 Employee Stock Purchase Plan, adding 1,056,096 shares to the reserve.
- Director Peter Harwin resigned effective May 27, 2026, with no disagreement with the company.
- Board size reduced from eight to seven directors.
- All three Class I director nominees (Mark McKenna, Cameron Turtle, Laurie Stelzer) were elected.
- KPMG LLP was ratified as independent auditor for fiscal year 2026.
- Say-on-pay proposal received 92.7% support from votes cast (excluding broker non-votes).
Financial Impact
No financial figures reported. The AR ESPP adds 1,056,096 shares to the reserve, representing potential future dilution of approximately 0.7% based on the company's market cap of $6.3B, but no immediate financial impact.
Risk Factors
- Potential future dilution from the 1,056,096 ESPP share reserve, though minimal relative to current market cap.
- Board reduction from eight to seven may concentrate decision-making, but no immediate concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000056 |
| Document: syre-20260527.htm | 0001636282-26-000056 |
| Document: 0001636282-26-000056-index-headers.html | 0001636282-26-000056 |
| Document: 0001636282-26-000056-index.html | 0001636282-26-000056 |
| Document: 0001636282-26-000056.txt | 0001636282-26-000056 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 15 of 21 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers